First Patient Dosed in NEXUS Phase 2 Trial of Leriglitazone in CALD
News
A Phase 2 trial evaluating leriglitazone, Minoryx Therapeutics‘ investigational oral therapy for boys with cerebral adrenoleukodystrophy (CALD), has dosed its first patient ... Read more